Confocal laser endomicroscopy predicts response in patients with acute inflammatory bowel disease undergoing anti-integrin therapy with Vedolizumab.

被引：0

作者：

Ellrichmann, Mark ^{[1
]}

Bethge, Johannes ^{[1
]}

Aust, Golo ^{[1
]}

Arlt, Alexander ^{[1
]}

Brandt, Berenice ^{[1
]}

Zeissig, Sebastian ^{[1
,2
,3
]}

Nikolaus, Susanna ^{[1
]}

Aden, Konrad ^{[1
]}

Schreiber, Stefan ^{[1
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Med 1, Campus Kiel, Kiel, Germany

[2] Tech Univ Dresden, Dept Med 1, Dresden, Germany

[3] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Dresden, Germany

来源：

GASTROINTESTINAL ENDOSCOPY | 2016年 / 83卷 / 05期

关键词：

D O I：

10.1016/j.gie.2016.03.113

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

574

引用

页码：AB154 / AB154

页数：1

共 50 条

[41] Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
Sierra Morales, M.
Birdi, S.
Samaan, M. A.
Brown-Clarke, C.
Duncan, J.
Stanton, A.
Koumoutsos, I.
Anderson, S.
Ray, S.
Mawdsley, J.
Sanderson, J.
Irving, P. M.
JOURNAL OF CROHNS & COLITIS, 2018, 12 : S451 - S452
[42] EFFECT OF VEDOLIZUMAB DOSE ESCALATION ON RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Shivashankar, Raina
Ladd, Antonio H. Mendoza
Grace, Rory
Aberra, Faten
Lichtenstein, Gary R.
GASTROENTEROLOGY, 2017, 152 (05) : S77 - S77
[43] VEDOLIZUMAB DOSE ESCALATION AS A WAY OF RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Birdi, S.
Sierra Morales, M.
Samaan, M. A.
Brown-Clarke, C.
Stanton, A.
Ray, S.
Koumoutsos, I.
Mawdsley, J.
Anderson, S.
Sandersdon
Irving, P. M.
GUT, 2018, 67 : A69 - A70
[44] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
Levartovsky, A.
Cohen, I.
Abitbol, C. M.
Yavzori, M.
Fudim, E.
Picard, O.
Kopylov, U.
Ben-Horin, S.
Ungar, B.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
[45] Assessment of Serum Biomarkers associated with Vedolizumab Therapy Response in Inflammatory Bowel Disease.
O'Connell, J.
Argue, R.
Dunne, M.
O'Connell, F.
Breslin, N.
Cullen, G.
Doherty, G.
Dunne, C.
Hartery, K.
Ismail, M. S.
MacCarthy, F.
McDonagh, P.
McKiernan, S.
McNamara, D.
Mulcahy, H.
O'Connor, A.
Ryan, B.
Sheridan, J.
O'Sullivan, J.
Kevans, D.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I299 - I299
[46] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
Levartovsky, A.
Cohen, I.
Abitbol, C. M.
Yavzori, M.
Fudim, E.
Picard, O.
Kopylov, U.
Ben-Horin, S.
Ungar, B.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
[47] Response to vedolizumab therapy in patients with inflammatory bowel disease: Impact of drug levels, anti-drug antibodies and α4β7 target occupancy
Ungar, B.
Kopylov, U.
Yavzori, M.
Fudim, E.
Picard, O.
Lahat, A.
Coscas, D.
Waterman, M.
Haj-Natour, O.
Orbach-Zingboim, N.
Mao, R.
Chen, M.
Chowers, Y.
Eliakim, R.
Ben-Horin, S.
JOURNAL OF CROHNS & COLITIS, 2018, 12 : S350 - S351
[48] Anti-TNF Agents May Pose a Higher Risk of Infection Than Anti-Integrin Agents in Treating Inflammatory Bowel Disease
Shah, Eric D.
Siegel, Corey A.
Chong, Kelly
Melmed, Gil
GASTROENTEROLOGY, 2015, 148 (04) : S233 - S233
[49] Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease
Dubinsky, Marla C.
Cross, Raymond K.
Sandborn, William J.
Long, Millie
Song, Xue
Shi, Nianwen
Ding, Yao
Eichner, Samantha
Pappalardo, Brandee
Ganguli, Arijit
Wang, Anthony
INFLAMMATORY BOWEL DISEASES, 2018, 24 (09) : 1876 - 1882
[50] Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies
Hoog, C.
Eberhardson, M.
Almer, S.
JOURNAL OF CROHNS & COLITIS, 2016, 10 : S310 - S310

← 1 2 3 4 5 →